Aktionärsstruktur

Inhaber in %
Financière de Tubize SA 35,00
Wellington Management Co. LLP 6,62
UCB SA 3,46
The Vanguard Group, Inc. 1,72
Norges Bank Investment Management 1,45
BlackRock Fund Advisors 1,42
Wellington Management International Ltd. 1,02
Amundi Asset Management SA (Investment Management) 0,70
Invesco Asset Management Deutschland GmbH 0,67
Assenagon Asset Management SA (Germany) 0,50
BlackRock Advisors (UK) Ltd. 0,45
Dimensional Fund Advisors LP 0,42
UBS AG (Investment Management) 0,37
JPMorgan Asset Management (UK) Ltd. 0,37
APG Asset Management NV 0,36

*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.

Personal

2014 2015 2016 2017 2018
Personal am Ende des Jahres 8.684 7.788 7.563 7.478 7.495
Umsatz pro Mitarbeiter in Mio. EUR 0,39 0,50 0,55 0,61 0,62

Bilanz (in Mio. EUR) - Aktiva

2014 2015 2016 2017 2018
Summe Umlaufvermögen 2.501 2.838 2.331 2.677 2.950
Summe Anlagevermögen 7.121 7.880 7.185 7.386 7.809
Summe Aktiva 10.148 10.956 10.212 9.917 10.514

Bilanz (in Mio. EUR) - Passiva

2014 2015 2016 2017 2018
Gesamtverschuldung/ -verbindlichkeiten 2.414 2.503 1.601 1.573 1.499
Summe Fremdkapital 5.601 5.705 4.735 4.181 4.259
Summe Eigenkapital 4.547 5.251 5.477 5.736 6.255
Summe Passiva 10.148 10.956 10.212 9.917 10.514

Adresse

Allée de la Recherche, 60, 1070 Brussels
Telefon 3225599999
Fax 3225599900
Internet http://www.ucb.com

Management

Albrecht de Graeve
Independent Director
Alexander Moscho, PhD
Chief Strategy Officer & Executive Vice President
Alice Dautry-Varsat, PhD
Independent Director
Antje Witte
Vice President-Investor Relations
Bharat Tewarie MD, MBA
Chief Marketing Officer & Executive VP
Bill Silbey
Executive Vice President & General Counsel
Caroline Vancoillie
Chief Accountant Officer
Charl van Zyl, MBA
Chief Operating Officer
Charles-Antoine Janssen
Director
Cristina C. Bautista, MBA
Senior Director-Global Internal Audit
Cyril Janssen
Director
Detlef Thielgen
Chief Financial Officer & Executive Vice President
Dhavalkumar Patel, PhD
Chief Scientific Officer & EVP
Dominique Baeten
Head-New Patient Value Mission
Emmanuel Caeymaex
Executive VP & Unit Head-Immunology Patient Value
Evelyn du Monceau
Chairman
Herman de Prins
Chief Information Officer
Iris Löw-Friedrich MD, PhD
Chief Medical Officer & Executive Vice President
Isabelle Ghellynck
Associate Director-Investor Relations
Jean Luc Fleurial
Chief Talent Officer
Jean-Christophe Tellier, MD
Chief Executive Officer & Executive Director
Jonkheer Cédric van Rijckevorsel
Director
Kay Dame Davies
Independent Director
Laurent Schots
Head-Corporate Communications & Media Relations
Nathalie Deldime
Manager-Investor Relations
Neil Weir, PhD
Senior Vice President-Discovery
Norman J. Ornstein, PhD
Independent Director
Pascale Richetta, MD
Executive Vice President
Pierre Gurdjian, MBA
Vice Chairman
Raf Remijsen
Head-Treasury & Risk Management
Roch F. Doliveux PhD, MBA
Director
Thomas Debeys
Head-Tax
Ulf Arne Wiinberg
Independent Director
Viviane Monges
Independent Director
Xavier Michel
Secretary & Vice President